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A neuroendocrine perspective
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ABSTRACT. Previous studies have elucidated a neuroendocrine mechanism consisting of the
hypothalamus (growth hormone releasing hormone, GHRH) – pituitary (growth hormone, GH) –
STAT5a/b axis that underlies sex-biased gene expression in the liver. It is now established that male
vs female patterned secretion of GHRH, and thus of circulating GH levels (“pulsatile” vs “more
continuous” respectively), leading to differently patterned activation of PY-STAT5a/b in hepatocytes
results in sex-biased gene expression of cohorts of hundreds of downstream genes. This review
outlines new data in support of a STAT5a/b-based mechanism of sex bias in the vascular disease
pulmonary hypertension (PH). Puzzling observations in PH include its 2-4-fold higher prevalence in
women but a male-dominance in many rodent models, and, paradoxically, inhibition of PH
development by estrogens in such models. We observed that conditional deletion of STAT5a/b in
vascular smooth muscle cells (SMC) in mice converted the male-dominant model of chronic
hypoxia-induced PH into a female-dominant phenotype. In human idiopathic PH, there was reduced
STAT5a/b and PY-STAT5 in cells in late-stage obliterative pulmonary arterial lesions in both men
and women. A juxtaposition of the prior liver data with the newer PH-related data drew attention to
the hypothalamus-GH-STAT5 axis, which is the major target of estrogens at the level of the
hypothalamus. This hypothesis explains many of the puzzling aspects of sex bias in PH in humans
and rodent models. The extension of STAT5-anchored mechanisms of sex bias to vascular disease
emphasizes the contribution of central neuroendocrine processes in generating sexual dimorphism in
different tissues and cell types.
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INTRODUCTION
Men and women and men have clear differ-
ences in prevalence of vascular disease.1,2 As
examples, the prevalence of hypertension, ath-
erosclerosis and coronary artery disease is
higher in men than in women.1,2 However, as a
converse example, the prevalence of pulmonary
hypertension (PH)a is 2-4-fold higher in women
than in men, even though after diagnosis,
women have a better outcome than men.3-6 In
many rodent models of arterial remodeling
after vascular injury (femoral artery cuffing or
common carotid artery ligation) or chronic hyp-
oxia-induced PH males show more extensive
vascular remodeling than females.6-19 In these
models the administration of estrogens [estra-
diol-17b (E2) or 2-methoxyestradiol (2-ME)] is
typically protective.6,16-19 This produces the
apparently paradoxical situation that in a dis-
ease like PH, while women have a higher prev-
alence than men, the typical rodent models of
PH (chronic hypoxia or monocrotaline admin-
istration) show a male dominance and E2
administration inhibits the latter.6,16-19 This
dichotomy between humans and rodents, and,
more generally, the varied differences in sex
biasb between men and women in vascular dis-
ease prevalence and models of vascular injury
remain incompletely understood.6,16-20 Indeed,
it has been especially perplexing to understand
the different sex-bias observations in similar
vascular disease situations in different species.
As examples, understanding the differences
between sex bias in PH in humans compared to
PH in rodent models, or even in understanding
the differences between models of PH in the rat
compared to the mouse (e.g. monocrotaline is
efficient in producing PH in the male rat, but
not in the mouse) has been a challenge.6,16-20
Thus far, the main mechanistic focus of various
studies to understand these situations has been
to focus almost exclusively on the direct effects
of E2 or other sex hormones on vascular cells.
As examples, there is an extensive literature on
the effects of E2 on increasing the function of
eNOS in endothelial cells, the ability of E2 to
stimulate vascular smooth muscle cell prolifer-
ation, and to inhibit the trafficking of vasorele-
vant receptors such as BMPR2 (bone
morphogenetic receptor 2) to the cell sur-
face.6,21-28 However, these studies of direct
effects of sex hormones on vascular cells, taken
together, have been unable to explain the many
disparate sex bias observations in a vascular
disease such as PH in humans and different
rodent species.
A Neuroendocrine Mechanism
(Hypothalamus-GH-STAT5) Underlying
Sex-Biased Gene Expression in the Liver
There are a series of relevant and critical
insights pertaining to mechanisms determining
sex-biased gene expression in the liver that
have not quite percolated into the vascular dis-
ease literature.29 The pharmacologic issue driv-
ing extensive studies of sex bias in liver gene
expression was the difference between men and
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women (and male vs female animals) to metab-
olize administered xenobiotics. Thus a major
focus of these studies was the sex-biased
expression of individual members of the P450
cytochrome (CYP) enzyme family that metabo-
lize medications. It was observed that, in the
rat, CYP2A2, 2C11 and 3A2 were male-biased,
but 2C12 female-biased, with 2C6 expressed in
both sexes.29-35 There were species-specific dif-
ferences: CYP3A subfamily was male-biased in
rats, but female-biased in humans and
mice.29-35 Administration of estrogens or tes-
tosterone into rodents, respectively “feminized”
or “masculinized” CYP enzyme expression.29
As in most of the vascular biology literature
today, investigators in liver-gene expression in
the early 1970s considered this sex-biased
expression to be mainly the result of direct
effects of sex hormones (estrogens and testos-
terone) on the hepatocyte.36
A critical discovery in 1973 by Colby et al.37
was the observation that the feminizing effect
of an injection of E2 into a rat or a mouse on
sex-biased liver gene expression was indirect
and had an absolute dependence on the pitui-
tary. This has since been extensively confirmed
- the feminizing effects of exogenously admin-
istered E2 or the masculinizing effects of tes-
tosterone on sex-biased gene expression in the
liver are blocked by hypophysectomy.29,38-48
The major target of injected E2 (and other sex
hormones) is the hypothalamus, in particular
the arcuate nucleus.49-54 [Note that there is no
blood-brain barrier at the arcuate nucleus and
additional “circumventricular” regions in the
brain.] As subsequently elucidated in detail by
Waxman et al and other investigators in the
last 2 decades a neuroendocrine mechanism of
sex-bias, operating through an axis consisting
of the arcuate nucleus-growth hormone releas-
ing hormone (GHRH)-growth hormone (GH)-
signal transducer and activator of transcription
5 (STAT5) accounts for sex-biased expression
of >1000 genes in the liver, and other tissues
of the body.29,46-59 The generation of sexual
dimorphism at the level of the hypothalamus
results from the male vs female patterned secre-
tion of GHRH and corresponding patterns of
GH secretion (Fig. 1).29,30,60-66 This has been
extensively confirmed in mice, rats and humans
(Fig. 2 is an example of human data).29,30,60-66
Circulating GH levels in the male (M) are
referred to as “pulsatile” (2-4 peaks per day)
with very low interpulse levels; in the female
(F) there is a higher frequency of pulses (>7
peaks/day) with significant interpulse levels,
FIGURE 1. Mean plasma GH levels in female and male rats, 45 and 90 days old, sampled at 30-
min intervals for a 6-h period. The number of animals in each group is shown in parenthesis. Verti-
cal lines represent the SEM. Adapted from Eden (1979) with permission of The Endocrine Soci-
ety.60
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thus this is called “more continuous” (Figs. 1
and 2). This results in M vs F patterned activa-
tion of PY-STAT5a/b in the distal tissues
(Fig. 3) and downstream of that a major cascade
of sex-specific gene expression of >1,000
genes.29,67 Even when assayed at a single time-
point in humans (in the morning after fasting)
the median value of serum GH levels was 80-
120 fold higher in women than in men.66 This is
a higher sexual dimorphism ratio than that for
E2 (ratio: 2.2 female bias) or testosterone (ratio:
14 male bias) observed in the same sera.66
Mice, rats and humans have quantitative
differences in the respective male vs female
patterns of circulating GH.27 (Figs. 1 and 2).
Human males show GH pulses of high magni-
tude, with very low interpulse levels; how-
ever, women show a more continuous level of
GH 100-fold higher than in the male
(Fig. 2).30,60-66 In contrast, male rats show
discrete pulses approximately every 3-4 hr
with little or no circulating GH detectable
during the interpulse interval.30 (Fig. 1). In
female rats, the pulses are more frequent, the
pulse heights are lower and the interpulse lev-
els are higher.30 (Fig. 1). Male mice also
have a pulsatile pattern; female mice have a
pattern that tends to have a higher frequency
FIGURE 2. Sex-bias in circulating GH levels in male and female humans. Panels A and B: repre-
sentative profiles of plasma GH levels showing that both men and women have pulsatile GH levels,
but there is a higher overall level of GH in women. Adapted from Winer et al (1990) with permission
of The Endocrine Society.61
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but with low interpulse levels.62 Thus a differ-
ence between female humans and female
rodents (rat or mouse) is in the much higher
continuous GH levels in women compared to
female rodents.(Figs. 1 and 2).
It needs emphasis that a major signaling
mechanism activated by GH in target tissues is
the Jak2-STAT5a/b pathway (Fig. 3A).29,67
Thus the regulation of gene expression by GH
(activation or repression) is mediated by low-
level activation of PY-STAT5 in M vs F pat-
terns.29,67 (Fig. 3A). This patterned PY-STAT5
activation, in combination with other transcrip-
tion factors (HNF4, HNF6, C/EBP), transcrip-
tionally activated or repressed cohorts of
hundreds of genes in hepatocytes. Cascades of
downstream gene expression included
regulation by STAT5-mediated patterned acti-
vation of master transcription repressors or
activators such as BCL6 and Cux2.29,57-59,67
This generates a cascade of sex-biased gene
expression but without the direct effect of any
steroid sex hormone (Fig. 3B). Parenthetically,
STAT5a and STAT5b are ubiquitous 90 kDa
cytoplasmic proteins that are 96% related to
each other and are derived from adjacent genes
at the STAT5a/b locus in both mouse and
man.29,67 STAT5a and STAT5b have overlap-
ping as well as some discrete functions.29,67 Of
the 7 STAT transcription factors, STAT5a and
STAT5b are the only ones implicated in medi-
ating sex-biased gene expression.29,67
Waxman and colleagues, and others, have
shown in detailed studies (29,67 and citations
FIGURE 3. Schematics illustrating concepts of how male (pulsatile) vs female (more continuous)
patterns of circulating GH elicit patterned activation of PY-STAT5 in the rat liver (Panel A), and thus
sex-biased gene expression (Panel B). Schematics adapted from Waxman and O’Connor (2006)
with permission of The Endocrine Society.67
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therein) that sex-biased expression of genes by
GH-STAT5 activation in the hepatocyte
depends on a “dynamical” signaling process
that involves multiple activation and inactiva-
tion cycles (frequency as in “pulsatile” or
“continuous”), differences in magnitude of sig-
nal strength (“level” of GH), the rates of these
changes (different slopes) resulting in different
rates of association of different transcription
regulatory proteins (including PY-STAT5a/b)
at the level of the chromatin encompassing dif-
ferent genes (Fig. 3). It is these differences in
signal strength, frequency, slopes of the activa-
tion and inactivation reactions, and in co-asso-
ciated proteins that lead to different chromatin
conformations (active or inactive for RNA tran-
scription) in the DNA context of different
genes. The net result is a cellular phenotype
driven by the GH-STAT5 axis consisting of the
sex-biased expression of hundreds of genes dif-
ferently in different species (Fig. 3). This pat-
terned activation of cells includes longer-lived
chromatin remodeling at the respective male
and female-specific genes in that respective
male-derived hepatocytes were more respon-
sive to the male pulsatile pattern of GH in cul-
ture, and female-derived less so.29,33
Different aspects of the specific GH patterns
affect sex-biased expression of the same genes
differently in different species.31-35 As an
example the CYP3A subfamily is male-biased
in rats, but female-biased in mice and
humans.29,31-35 We note that CYP3A has been
shown to be induced by GH through STAT5,68
and in an issue relevant to pulmonary hyperten-
sion, it is the CYP3A subfamily of enzymes
that convert the injected inactive monocrotaline
(MCT) to the bioactive monocrotaline pyrrole
(MCTP) in male rats,69,70 Thus it is no surprise
that MCT administration into a male rat produ-
ces PH more efficiently than in the female.6,17
Sex Bias and STAT5a/b in Vascular
Disease
We mentioned earlier that in rodents aortic
remodeling after a balloon injury or pulmonary
arterial remodeling after exposure to chronic
hypoxia was more pronounced in males,
although the mechanisms have not been eluci-
dated.6-15 In vascular smooth muscle cells
(SMCs), PY-STAT5b has been identified as a
transcription factor which facilitates growth and
motility, and neointima formation in response
to thrombin, PDGF and arterial injury.21-25,71-74
Suppression of activation of PY-STAT5b sig-
naling in the vessel wall reduced balloon
injury-induced neointima formation.73 Remark-
ably, that hypophysectomy in the male rat
markedly impaired arterial remodeling after aor-
tic balloon injury due to reduced vascular SMC
proliferation and myointima formation, was
reported in 1978,75 and confirmed,76 but the
mechanisms remained to be elucidated. It is
now known that GH promotes vascular SMC
proliferation and migration, and is required for
normal vascular reactivity and remodeling.77-80
Indeed, the prevalence of systemic hypertension
is 20-50% in patients with acromegaly (in
whom the plasma GH levels are high) due to
“stiffer arteries.”77-80 Nevertheless, the issue of
the GH-STAT5 axis contributing to sex bias in
vascular remodeling has received little attention.
Our interest in the functions of STAT5 spe-
cies (both unphosphorylated U-STAT5 and Tyr-
phosphorylated PY-STAT5) in vascular biology
and sex bias arose several years ago from the
discovery that U-STAT5a/b and STAT5a-GFP
associated with the endoplasmic reticulum (ER)
and Golgi apparatus in pulmonary arterial endo-
thelial and smooth muscle cells.81,82 siRNA
mediated knockdown of U-STAT5a/b in vascu-
lar cells (a) produced a remarkable cystic ER/
lunate nucleus phenotype, and (b) inhibited traf-
ficking of the tsO45 VSV-G-GFP glycoprotein,
and vasorelevant receptors such as BMPR2 to
the cell surface.81,82 Moreover, the inhibition of
intracellular trafficking of BMPR2 to the cell
surface by siRNA-mediated knockdown of
STAT5a/b was combinatorially exacerbated by
estradiol-17b (E2).82 These observations, and
the data of Waxman and colleagues implicating
STAT5 in mediating sex bias in liver gene
expression,29,67 led us to ask whether STAT5
might underlie the sex bias seen in a vascular
disease such as PH.
Our approach83 to test the hypothesis relat-
ing sex and STAT5a/b in vascular remodeling
has been to develop novel mice lines which
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have a conditional vascular smooth muscle-
specific deletion of the floxed STAT5a/b locus
using the SM22a-Cre method [heterozygous
SM22a-Cre, STAT5a/b fl/wt (designated
“C/¡”) and homozygous SM22a-Cre, STAT5a/
b fl/fl (designated “¡/¡”)]. In such mice both
the adjacent STAT5a and STAT5b were deleted
in SMCs, especially vascular SMCs.83 In
contrast to endothelial-cell-specific STAT5a/b
knockout mice (produced using the Tie2-Cre
approach) which have microcytic anemia and
are difficult to maintain postnatally,54 the
SMC-specific STAT5a/bC/¡ and ¡/¡ knock-
out mice were fertile and viable.83
For our initial studies in these conditional
SMC:STAT5a/b knockout mice, we focused on
the sex-biased response to chronic hypoxia. It
is well known that in the wt mouse chronic
hypoxia typically triggers a male-dominant pul-
monary arterial remodeling with female mice
showing less extensive changes.6,16-19 Hypoxia
has been shown to activate PY-STAT5 in can-
cer cells in culture.84 We observed that
although male and female mice had equal lev-
els of STAT5a/b expression in pulmonary
arterial walls in lung sections and in isolated
PASMCs,83 mice subjected to chronic hypoxia
showed a sex-bias in the level of PY-STAT5
activation in the pulmonary arterial walls -
greater level of activation in the female than in
the male (Fig. 4). An investigation of the effect
of conditional STAT5a/b knockout on PH
induced by chronic hypoxia revealed that the
male dominance was abrogated in the hypoxic
STAT5a/b C/¡ and ¡/¡ mice (Figs. 5 and
6).83 Overall, female STAT5a/b C/¡ and ¡/¡
developed the greatest increase in right ventric-
ular systolic pressure (RVSP), in right ventricu-
lar hypertrophy (RVH) and in pulmonary
arterial remodeling (Figs. 5 and 6).83 Addition-
ally, knockout males also had more severe
PH than wt males (Fig. 6). These data provided
the first evidence implicating STAT5a/b in the
sexual dimorphism observed in a vascular dis-
ease process. At the cellular level this increased
severity of PH in hypoxic STAT5a/b knockout
mice involved marked hypertrophy of SMCs in
the pulmonary arterial tunica media.83
The effects of a knockout of STAT5a/b in
vascular SMCs likely extend beyond the
FIGURE 4. Sex-biased activation of PY-STAT5a/b in pulmonary arterial walls in wild-typemice after
7 weeks of chronic hypoxia (expt. as in Fig. 6). At the conclusion of the experiment in Fig. 6, quanti-
tative immunofluorescence was used to evaluate levels of PY-STAT5a/b in the arterial walls of pul-
monary arterial segments in sections of lungs using methods previously described (83). *P <0.05
in comparisons between hypoxia and normoxia groups of the 2 sexes; and also in the male vs
female hypoxia comparison; scale bar D 50 mm.
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pulmonary circulation. Although, the male and
female SMC:STAT5a/b¡/¡ mice had similar
systolic, diastolic and mean blood pressures as
respective wt mice,83 “resistance” arteries such
as second-order mesenteric arteries isolated
from the knockout mice were 10-100-fold less
responsive to vasodilation by acetylcholine
(Fig. 7). Whether there is a STAT5-dependent
sex bias in the mesenteric artery vasodilation
response to acetylcholine is as yet unclear.
Reduced of STAT5a/b in SMCs in
Vascular Lesions in Human Idiopathic
Arterial Pulmonary Hypertension (IPAH)
Quantitative immunofluorescence analyses
showed a marked reduction of STAT5a/b and
of PY-STAT5 in SMCs in obliterative vascular
lesions in lung sections derived from both male
and female patients with late-stage IPAH, albeit
with some variations between patients and in
lesions in the same patient (Fig. 8).20,83 We
have previously reported changes in the organi-
zation of the endoplasmic reticulum (ER)-asso-
ciated proteins atlastin-3 (ATL3) and reticulon-
4 (RTN4) (also called NogoB) in vascular ECs
and SMCs following siRNA-mediated knock-
down of STAT5a/b.81 Thus we evaluated
expression of ATL3 and RTN4 in cells in IPAH
lesions. Expression of ATL3 was markedly
reduced but that of RTN4 was increased.83
These data, taken together with our previous
observations of an increase in Golgi apparatus-
associated tether giantin and SNARE Vti1a in
such cells,85 point to the occurrence of ER
stress and of changes in intracellular trafficking
in cells in such obliterative arterial lesions.
We then investigated the expression of a
known STAT5-dependent gene target in such
FIGURE 5. Abrogation of the male dominance of PH in the chronic hypoxia model in mice with het-
erozygous SM22-Cre, STAT5a/bC/¡ deletion (7 weeks’ of hypoxia; nD 5 per group). Panel A,
RVSP; Panel B, RVH; Panels C, PA remodeling in terms of wall thickness; Panel D: PA remodeling
in terms of SMA-positive vessels; Panel E, Van Gieson’s elastin staining. Scale bar D 45 mm). *P
<0.05. Adapted from Sehgal et al (2014).83
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lesions – the master transcription repressor
BCL6. Waxman and colleagues have shown
that BCL6 expression is driven by the GH-
STAT5 axis in hepatocytes (male-biased in the
liver), that the DNA binding motifs of STAT5
and BCL6 are very similar, and that BCL6 can
repress STAT5 expression.57-59 The data
obtained showed a marked reduction of BCL6
in cells in obliterative IPAH lesions
(Fig. 8).20,83 This loss of BCL6 is consistent
with the overall thinking about IPAH pathogen-
esis today in that (a) it is known that genetic
deletion of BCL6 in mice results in a hypercy-
tokine production state which includes pulmo-
nary vasculitis,86-88 and (b) that several
investigators have proposed that the PH disease
process involves localized pulmonary vascular
inflammation.89-92 Thus, a reduction in BCL6
in cells in obliterative lesions of IPAH (Fig. 8)
is consistent with development of a localized
proinflammatory state. However, lung sections
from both men and women with IPAH showed
reduced BCL6 expression, perhaps because the
sections available were from patients with late-
stage disease (Fig. 8).20,83
In considering sex bias in the pathogenesis
of PH in humans (and in rodent models) we
need to keep in mind 2 separate issues. First is
the contribution of intact levels of STAT5a/b
and PY-STAT5 as part of the GH-STAT5 axis
in the early stages of the disease to mediating
sex bias in humans (the 2-4-fold higher preva-
lence in women than in men) and in rodent
models (typically male-dominance with, para-
doxically, inhibition of PH by E2). Second is
loss of STAT5a/b, PY-STAT5 and BCL6 in the
late stages of IPAH in both men and women.
These two issues get combined in the hypoxic
FIGURE 6. Female mice develop the severest PH in response to chronic hypoxia after homozygous
SM22-Cre, STAT5a/b¡/¡ deletion (7 weeks’ of hypoxia; nD 5 per group). Panel A, RVSP; Panel B,
RVH; Panels C, PA remodeling in terms of wall thickness; Panel D: PA remodeling in terms of
SMA-positive vessels; Panel E, Van Gieson’s elastin staining. Scale bar D 45 mm).
*P <0.05. Adapted from Sehgal et al (2014).83
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SMC:STAT5a/b¡/¡ mouse model in which (a)
the sex bias is reversed, and (b) females get
more severe disease than males. What downre-
gulates STAT5a/b levels in IPAH lesions in
late stage disease in both men and women
remains to be understood.
Reduced STAT5a/b in Hypertrophic
PASMC Lines Isolated From IPAH
Patients
The above immunofluorescence data derived
from lung sections of IPAH patients showing
reductions in STAT5a/b obliterative lesion
raised the question whether cells derived from
lung vessels of IPAH patients might also show
such reductions. A corollary question was
whether vascular cells with reduced STAT5
derived from IPAH patients might display cell
hypertrophy and organellar changes. Cell
imaging studies of the primary PASMC lines
derived from female controls and IPAH
patients showed that 9 out of 9 control SMC
lines consisted of small cells, while 7 out of 11
IPAH SMC lines consisted of enlarged hyper-
trophic cells, with markedly enlarged Golgi
apparatus (displayed using either anti-giantin
or ant-Vti1a antibodies).83 Western blot
analyses showed a correlation between the
cluster of these hypertrophic SMC lines and
reduced STAT5a expression (using the k-
means cluster statistic).83 Thus, low STAT5
expression clustered with cell hypertrophy, and
enlarged Golgi apparatus in female IPAH-
derived SMC lines in a multi-parameter pattern
(not enough numbers of male-derived lines
were available for study). These data provided
further evidence for the involvement of a loss
of STAT5 in the pathogenesis of PH.
A Neuroendocrine Perspective
(Hypothalamus-GH-STAT5) of Sex Bias
in PH
The previous literature about how the hypo-
thalamus-GH-STAT5 axis underlies sex bias in
liver gene expression, juxtaposed with the new
data on the role of STAT5 in determining sex
bias in hypoxic PH in a mouse model, and the
puzzling sex-bias questions in the PH literature
provides us with an opportunity to suggest a
synthesis of these different lines of research.
(Fig. 9; a more detailed synthesis is in ref. 20).
Why is prevalence of IPAH higher in women
than in men? On average, women have 80-120-
fold higher levels of circulating GH than
FIGURE 7. Resistance arteries (second-order mesenteric arteries) are “stiffer” in mice with homo-
zygous SM22-Cre, STAT5a/b¡/¡ deletion. The phenotypes of isolated pressurized (80 mm Hg)
resistance arteries derived from groups of male and female wt and mutant mice were evaluated in
terms of the vasorelaxation response to acetylcholine (Ach) using methods as in ref.112 and
expressed as % change in peripheral diameter (% PD)(pooled data from n D 4 per group; mean
§SE). *P < 0.05 comparing respective wt and knockout groups (pooling both sexes) by ANOVA.
10 Sehgal et al.
men.66 Moreover this is in a more continuous
pattern than in men (Fig. 2).20,29,61 It is known
that GH promotes vascular smooth muscle cell
proliferation and migration, and is required for
normal vascular reactivity and modeling.77-80
We propose that these 80-120-fold higher lev-
els and a more continuous pattern of GH, and
thus activation of different sets of cell-cycle,
celL-proliferation and cell-migration regulatory
genes,29 is why IPAH is more prevalent in
women than men.(Fig. 9).
What is the relevant difference between a
female human and a female rodent underlying
differences in sex bias in PH? There are quanti-
tative differences in patterns of circulating GH
in males and females in mice, rats and humans
resulting in the same gene being regulated dif-
ferently in terms of sex-specificity in the 3 spe-
cies (Figs. 1, 2 and 3)(discussed in detail in
refs).20,29,67 The major relevant difference
between female humans and female rodents is
in the much higher continuous GH levels in
women compared to female rodents (Fig. 2).
Thus expression of P450 CYP 3A subfamily
genes is male-biased in the rat,30,31 but female-
biased in humans.34
Is there really an estrogen paradox? We have
suggested above that the basis for why women
get more IPAH than men may be related to the
80-120-fold higher GH levels and not so much
E2.66 In animal models, typically in male
rodents, E2 would be protective by targeting
FIGURE 8. Representative immunofluorescence images showing coordinate reductions in
STAT5a/b, PY-STAT5 and BCL6 in obliterative pulmonary arterial lesions in male and female
patients with late-stage IPAH compared to control arterial walls (white arrows). The patient num-
bers correspond to the listing in Supplemental Table 2 in ref. 83. Scale bar D 50 mm.
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the hypothalamus directly.49-54 Thus, as has
been shown in the liver literature, E2 would
"feminize" GH patterns changing the male pat-
tern of expression in rodents to a female pattern
(Fig. 1). Therefore the apparent paradox can be
explained by involving GH in human IPAH,
and by the direct targeting of the hypothalamus
by E2 (Fig. 9).20,83
Why is the MCT model male-biased in the
rat?6,16,17 Downstream of the GH/STAT5 axis
is the sex-specific expression of P450 CYP3A
subfamily members.29,30,31,34 STAT5 is
the transcription factor that upregulates
CYP3A.29,68 and it is the CYP3A subfamily
enzymes that metabolize MCT to its active
MCTP.69,70 In the rat this is male-biased but is
female-biased in mouse and humans.29-31,34
Thus, a single injection of MCT efficiently
induces PH in the male rat. However, MCT
does not readily produce PH in the female
mouse either suggesting the occurrence of addi-
tional inter-species differences.
Why do female mice overexpressing the
serotonin transporter (SERT) or the S100 cal-
cium-binding protein S100A4/mts1 or the
dexfenfluramine-administered mice, but not
male mice, develop modest PH after 5
months?93-97 Although increased serotonin (5-
HT) has been implicated in the pathogenesis
of PH,93-97 the mechanistic focus has largely
been on direct effects of 5-HT on pulmonary
vascular tissues. We note that it is already
known that the PH-causing anorexigens fen-
fluramine, aminorex, phentermine and
fluoxetine increase 5-HT in the hypothala-
mus.98-101 and that fenfluramine blunted GH
responsiveness to GHRH.102 Additionally, it
is already known that PY-STAT5 signaling in
the hypothalamus is involved in regulating
appetite and sex-biased changes in body
weight.103 It has been shown already that 5-
HT suppresses STAT5 expression and PY-
STAT5 activation,104 and 5-HT-receptor and
dopaminergic D1, D2 receptor antagonists
also inhibit PY-STAT5 activation (e.g., pimo-
zide).105,106 We suggest that consideration of
mechanisms in such models also include the
central effects of 5-HT at the level of the
hypothalamus and the arcuate nucleus, and
sex-specific changes in the patterns of GH
secretion and STAT5 activation. The female-
biased PH in these circumstances is likely
generated at the level of the hypothalamus.
Why is there no sex bias in the hypoxia-
SU5416 model?6,18 SU5416 (Sugen) has been
described in the PH literature as an inhibitor of
receptor 2 for vascular endothelial growth factor
(VEGF R2)(6 and citations therein). However, it
has been shown already that SU5416 inhibits
activation of PY-STAT5.107 The inhibition by
SU5416 of PY-STAT5 activation [and of addi-
tional receptor tyrosine kinases108,109] suggests
why this model does not show a sex bias.
We emphasize that from our perspective,
outlined in Figure 9, we specifically combine
both central neuroendocrine mechanisms with
peripheral tissue-level mechanisms in the path-
ogenesis of a vascular disease such as PH.
FIGURE 9. The GH-STAT5-BCL6 neuroendocrine axis as it relates to sex-bias in the initiation and
progression of the pathogenesis of pulmonary hypertension.
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Discovering Sex-Biased and STAT5-
Dependent Gene Expression Patterns in
Vascular Cells
Investigations of sex bias and its GH-
STAT5-dependence in liver gene expression
using global unbiased microarray analyses of
expressed RNA have established an impor-
tant paradigm – the different expression pat-
terns include cohorts of hundreds of genes
that are male- or female-biased, that are up-
or down-regulated after hypophysectomy,
that are up- or downregulated upon GH
administration into hypohysectomized mice,
and that are up- or down-regulated in hepa-
tocytes from mice with a liver-specific
STAT5a/b¡/¡ knockout, or those that are
sex-biased but unaffected by any of these
manipulations (Fig. 3).29,67 Moreover, in
each of these instances, while there are some
genes that are coordinately affected similarly
in males and females (e.g. reduction of
SOCS2 expression after STAT5a/b¡/¡
knockout in males and females), the cohorts
of the affected genes in males and females
are largely different. The important point in
this paradigm is that sex-bias determinism
through the GH-STAT5 axis at the level of
peripheral tissues resides in changes in pat-
terns of gene expression of cohorts of hun-
dreds of genes (comprising transcription
factors, growth factors and cytokines, intra-
cellular trafficking mediators, cell adhesion
molecules, and proteins that regulate cell
proliferation, the cell cycle and apoptosis)
and not just one or a few “mediators.” Thus
this paradigm is different from the reduction-
ist approach of most investigators who ask
for identification of changes in one or a few
genes, and expect that to account for the
development of sex-biased phenotypes in dif-
ferent tissues. Moreover, such patterns of
sex-biased GH-STAT5-driven gene expres-
sion patterns are likely to be different in dif-
ferent tissue types in a particular species,
and also different in the same tissue type in
different species.
The availability of mice with SMC-spe-
cific STAT5a/b¡/¡ deletion allows for the
derivation of primary PASMC and aortic
SMC lines from males and females and an
investigation of sex- and STAT5-specific
patterns of gene expression using global
unbiased RNA microarray or RNA sequenc-
ing approaches. Similarly, the availability of
primary human PASMC lines derived from
IPAH patients (females in this instance) with
low STAT5 expression and corresponding
control lines with high STAT5 allows for a
similar investigation of STAT5-biased pat-
terns of gene expression. The identification
of BCL6 as a master transcription factor
downstream of STAT5 in sex determinism
hepatocytes by Waxman and colleagues,57-59
suggests the possibility that derivation of
mice with SMC-specific deletion of BCL6,
singly or in combination with STAT5a/b,
may also lead to mice that have lost the
male-dominant PH phenotype after exposure
to chronic hypoxia. Such studies are likely
to be informative with respect to the patho-
genesis of the human disease in that we
observed a marked decrease in BCL6 in
SMCs in obliterative arterial lesions in IPAH
(Fig. 8). The nestin-Cre-STAT5a/b¡/¡ mice
already developed by Lee et al.103 which
have deletion of STAT5a/b in the central ner-
vous system including the hypothalamus pro-
vide a substrate to directly test the role of
the hypothalamus in sex bias in the chronic
hypoxia model as proposed in Figure 9
(STAT5 and PY-STAT5 are the relevant
transcription factors in the hypothalamus that
regulate appetite, sexual dimorphism of body
weight, and insulin resistance).103
We note that GH and STAT5 are involved in
vascular SMC proliferation, motility and
remodeling after injury,71-75,77-80 and that
transgenic male mice overexpressing bovine
GH developed hypertension between 5 and 6
months of age, independent of their body-
weight.110 This hypertension then persisted
long-term.110 Such observations, together with
our data in Figure 7, implicate the GH-STAT5
axis in systemic vascular biology. The extent to
which the GH-STAT5 axis contributes to sex
bias in systemic vascular remodeling remains
an open question, but one that can now be
addressed using the conditional SMC-specific
STAT5a/b¡/¡ mice.
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Conclusions
Fifty years ago Frantz and Rabkin reported
observing markedly higher plasma GH levels
in fasting ambulatory women than in men.111
They also observed that administration of an
estrogen (diethylstilbestrol) to men
“feminized” the pattern of circulating GH, and
postulated that this was due to an effect of
estrogen on the pituitary or higher centers.
Over the next several decades these seminal
observations led to the development of the neu-
roendocrine perspective of sex-biased liver
gene expression anchored in hypothalamus-
GH-STAT5 mediated mechanisms. These
mechanisms, elucidated in great detail by
numerous investigators, have now proven use-
ful in understanding puzzling sex-bias issues in
the pathogenesis of the vascular disease pulmo-
nary hypertension in humans and rodent mod-
els. A critical insight transposed into vascular
biology from the prior liver literature is that
exogenously administered estrogens (and other
sex hormones) affect sex-biased gene expres-
sion in peripheral tissues by affecting neuronal
cells in the hypothalamus, and thus
“feminizing” (or “masculinizing”) the pattern
of GH secretion. This is an insight missing
from the vascular biology literature. The focus
of sex-bias studies in vascular biology thus far
has almost exclusively been on the direct
effects of sex hormones on vascular cells. The
inclusion of the neuroendocrine GH-STAT5
pathways in considering sexual dimorphism in
human disease and in rodent models broadens
our mechanistic perspective of how sex and
gender bias comes about. Part of this broaden-
ing of perspective includes the appreciation
that the generation of a net sex-biased pheno-
type in a particular cell type in a particular spe-
cies involves changes in the expression and
function of cohorts of hundreds of genes
through STAT5-anchored mechanisms, but
also inclusive of STAT5-independent mecha-
nisms. The paradigm at hand is one in which
STAT5 transcription factors, in association
with other cell-type-specific transcription fac-
tors, are transient activators or repressors of the
expression of large cohorts of genes in different
patterns depending upon the dynamical
properties of GH-STAT5 activation such that
the same pathways can contribute to both inhib-
iting or enhancing a particular disease process
depending upon sex and species, and the partic-
ular pulmonary hypertension circumstance.
The novel neuroendocrine concept, for the
moment, is that the GH-STAT5 axis connects
sexual dimorphism phenotype at the level of
peripheral vascular tissues to mechanisms at
the level of the hypothalamus.
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NOTES
aSome investigators use the phrase “pulmonary
arterial hypertension (PAH)” to generically encompass
the human disease and rodent models. Others use the
phrase “pulmonary hypertension (PH)” as the generic
term and reserve “pulmonary arterial hypertension
(PAH)” for different forms of the human disease [such
as idiopathic pulmonary arterial hypertension (IPAH)
or hereditary pulmonary arterial hypertension (HPAH)].
In this essay we follow the second approach, and use
PH as the generic term.
bThe phrase “sex bias” refers to biological differen-
ces, while the phrase “gender bias” refers to behavioral
and congnitive differences. Thus “sex bias” is appro-
priate throughout this article.
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